戻る
Clarity Pharmaceuticals Ltd (CLRPF)価格
CLRPF 株価推移チャート
CLRPF 収入
Clarity Pharmaceuticals Ltd
$2.3
2.22%
$0.04
終値： Jan 16, 16:00:00 GMT-5
$2.3
0%
$0
アフターマーケット：Jan 16, 20:00:00 GMT-5
主要データ
前終値
$2.25
始値
$2.3
当日レンジ
$2.3 - $2.3
52週レンジ
$0.842 - $3.6
取引高
--
平均取引高
3.1K
1株当たり利益(TTM)
-0.13
配当利回り
--
時価総額
$855.6M
CLRPFとは何ですか？
Clarity Pharmaceuticals Ltd. is a clinical stage radiopharmaceutical company. The company is headquartered in Eveleigh, New South Wales. The company went IPO on 2021-08-25. The firm is focused on developing targeted copper theranostics based on its SAR Technology Platform. The company is progressing clinical trials with its approximately three key products, SARTATE, SAR-bisPSMA, and SAR-Bombesin. Its lead product, SAR-bisPSMA, is progressing through over three clinical trials: one theranostic trial (SECuRE) and two Phase III diagnostic trials (CLARIFY and AMPLIFY). SARTATE is developed for diagnosing, staging, and treating cancers that express somatostatin receptor 2 (SSTR2). SAR-bisPSMA is developed for diagnosing, staging, and treating prostate cancer that expresses prostate-specific membrane antigen (PSMA). SAR-Bombesin is developed for identifying and selecting patients for subsequent treatment of cancers that express a specific receptor called the gastrin releasing peptide receptor (GRPr), including breast cancer and prostate cancer.